Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals

Talia Kustin, Noam Harel, Uriah Finkel, Shay Perchik, Sheri Harari, Maayan Tahor, Itamar Caspi, Rachel Levy, Michael Leschinsky, Shifra Ken Dror, Galit Bergerzon, Hala Gadban, Faten Gadban, Eti Eliassian, Orit Shimron, Loulou Saleh, Haim Ben-Zvi, Doron Amichay, Anat Ben-Dor, Dana Sagas, Merav Strauss, Yonat Shemer Avni, Amit Huppert, Eldad Kepten, Ran D. Balicer, Doron Nezer, Shay Ben-Shachar, View ORCID ProfileAdi Stern
doi: https://doi.org/10.1101/2021.04.06.21254882
Talia Kustin
1The Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
2Edmond J. Safra Center for Bioinformatics, Tel Aviv University, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Noam Harel
1The Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
2Edmond J. Safra Center for Bioinformatics, Tel Aviv University, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uriah Finkel
3Clalit Research Institute, Innovation Division, Clalit Health Services, Ramat Gan, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shay Perchik
3Clalit Research Institute, Innovation Division, Clalit Health Services, Ramat Gan, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sheri Harari
1The Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
2Edmond J. Safra Center for Bioinformatics, Tel Aviv University, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maayan Tahor
1The Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Itamar Caspi
1The Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachel Levy
1The Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Leschinsky
3Clalit Research Institute, Innovation Division, Clalit Health Services, Ramat Gan, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shifra Ken Dror
4Clalit Health Services, Central Laboratories, Haifa and Western Galilee, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Galit Bergerzon
4Clalit Health Services, Central Laboratories, Haifa and Western Galilee, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hala Gadban
4Clalit Health Services, Central Laboratories, Haifa and Western Galilee, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Faten Gadban
4Clalit Health Services, Central Laboratories, Haifa and Western Galilee, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eti Eliassian
5Progenin Laboratories, Jerusalem District, Clalit Health Services, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Orit Shimron
5Progenin Laboratories, Jerusalem District, Clalit Health Services, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Loulou Saleh
6Microbiology lab, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haim Ben-Zvi
6Microbiology lab, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Doron Amichay
7Central Laboratory, Clalit Health Services, Tel Aviv, Israel
8Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University, Beersheba, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anat Ben-Dor
7Central Laboratory, Clalit Health Services, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dana Sagas
9Microbiology Laboratory, Emek Medical Center, Afula, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Merav Strauss
9Microbiology Laboratory, Emek Medical Center, Afula, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yonat Shemer Avni
10Laboratory of Clinical Virology, Soroka University Medical Center. Beersheba, Israel
11Faculty of Health Sciences, Ben Gurion University of the Negev, Beersheba, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amit Huppert
12The Bio-statistical and Bio-mathematical Unit, The Gertner Institute for Epidemiology and Health Policy Research, Chaim Sheba Medical Center, Tel Hashomer, Israel
13The Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eldad Kepten
3Clalit Research Institute, Innovation Division, Clalit Health Services, Ramat Gan, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ran D. Balicer
3Clalit Research Institute, Innovation Division, Clalit Health Services, Ramat Gan, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Doron Nezer
14Clalit Health Services, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shay Ben-Shachar
3Clalit Research Institute, Innovation Division, Clalit Health Services, Ramat Gan, Israel
13The Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: shayb@clalit.org.il sternadi@tauex.tau.ac.il
Adi Stern
1The Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
2Edmond J. Safra Center for Bioinformatics, Tel Aviv University, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Adi Stern
  • For correspondence: shayb@clalit.org.il sternadi@tauex.tau.ac.il
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Summary

The SARS-CoV-2 pandemic has been raging for over a year, creating global detrimental impact. The BNT162b2 mRNA vaccine has demonstrated high protection levels, yet apprehension exists that several variants of concerns (VOCs) can surmount the immune defenses generated by the vaccines. Neutralization assays have revealed some reduction in neutralization of VOCs B.1.1.7 and B.1.351, but the relevance of these assays in real life remains unclear. We performed a case-control study that examined the distribution of SARS-CoV-2 variants observed in infections of vaccinated individuals (“breakthrough cases”) and matched infections of unvaccinated individuals. We hypothesized that if there is lower vaccine effectiveness against one of the VOCs, its proportion among the breakthrough cases should be higher than among unvaccinated cases. Our results show that vaccinees that tested positive at least a week after the second dose were indeed disproportionally infected with B.1.351, as compared with unvaccinated individuals (odds ratio of 8:1). Those who tested positive between two weeks after the first dose and one week after the second dose, were disproportionally infected by B.1.1.7 (odds ratio of 26:10), suggesting reduced vaccine effectiveness against both VOCs at particular time windows following vaccination. Nevertheless, the B.1.351 incidence in Israel to-date remains low and vaccine effectiveness remains high among those fully vaccinated. These results overall suggest that vaccine breakthrough infection may be more frequent with both VOCs, yet a combination of mass-vaccination with two doses coupled with non-pharmaceutical interventions control and contain their spread.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was supported by an ERC starting grant 852223 (RNAVirFitness), by an Israeli Science Foundation grant 3963/19, and by kind donations from the Millner and AppFlyer foundations. This study was supported in part by fellowships to TK, NH, and SH from the Edmond J. Safra Center for Bioinformatics at Tel-Aviv University.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the CHS institutional review board (IRB #0016-21-COM2) and was exempt from the requirement for informed consent. The study was further approved by the Tel-Aviv University ethics committee (0002706-1).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Clarifications were made to the text, no change in the results.

Data Availability

All sequences were uploaded to GISAID.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 16, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals
Talia Kustin, Noam Harel, Uriah Finkel, Shay Perchik, Sheri Harari, Maayan Tahor, Itamar Caspi, Rachel Levy, Michael Leschinsky, Shifra Ken Dror, Galit Bergerzon, Hala Gadban, Faten Gadban, Eti Eliassian, Orit Shimron, Loulou Saleh, Haim Ben-Zvi, Doron Amichay, Anat Ben-Dor, Dana Sagas, Merav Strauss, Yonat Shemer Avni, Amit Huppert, Eldad Kepten, Ran D. Balicer, Doron Nezer, Shay Ben-Shachar, Adi Stern
medRxiv 2021.04.06.21254882; doi: https://doi.org/10.1101/2021.04.06.21254882
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals
Talia Kustin, Noam Harel, Uriah Finkel, Shay Perchik, Sheri Harari, Maayan Tahor, Itamar Caspi, Rachel Levy, Michael Leschinsky, Shifra Ken Dror, Galit Bergerzon, Hala Gadban, Faten Gadban, Eti Eliassian, Orit Shimron, Loulou Saleh, Haim Ben-Zvi, Doron Amichay, Anat Ben-Dor, Dana Sagas, Merav Strauss, Yonat Shemer Avni, Amit Huppert, Eldad Kepten, Ran D. Balicer, Doron Nezer, Shay Ben-Shachar, Adi Stern
medRxiv 2021.04.06.21254882; doi: https://doi.org/10.1101/2021.04.06.21254882

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1099)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9781)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2317)
  • Geriatric Medicine (223)
  • Health Economics (462)
  • Health Informatics (1563)
  • Health Policy (737)
  • Health Systems and Quality Improvement (605)
  • Hematology (238)
  • HIV/AIDS (506)
  • Infectious Diseases (except HIV/AIDS) (11655)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (239)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2146)
  • Nursing (134)
  • Nutrition (338)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1183)
  • Ophthalmology (365)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (147)
  • Palliative Medicine (50)
  • Pathology (312)
  • Pediatrics (698)
  • Pharmacology and Therapeutics (302)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2187)
  • Public and Global Health (4672)
  • Radiology and Imaging (781)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)